United States-based AbbVie (NYSE: ABBV) announced on Friday that it has received approval from the United States Food and Drug Administration (FDA) for RINVOQ(R) (upadacitinib; 15 mg, once daily), intended to treat adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) blockers.
The product received approval based on the efficacy and safety data from a Phase three SELECT-AXIS 2 clinical trial (Study 1) assessing RINVOQ in patients displaying inadequate response or intolerance to one or two biologic disease-modifying anti-rheumatic drugs (bDMARDs), and the Phase 2/3 SELECT-AXIS one clinical trial assessing RINVOQ in patients who were naive to bDMARDs and had an inadequate response or intolerance to at least two nonsteroidal anti-inflammatory drugs (NSAIDs).
Atul Deodhar MD, professor of medicine and medical director of the Rheumatology Clinics for the Division of Arthritis and Rheumatic Diseases at Oregon Health & Science University, and investigator of the SELECT-AXIS 1 trial, said: "Many patients with ankylosing spondylitis do not achieve disease control with current biologic therapies and additional treatments are needed to help relieve the signs and symptoms of this disease. With today's FDA approval, patients who do not respond to a TNF inhibitor have an additional oral treatment option, in partnership with their rheumatologist, to help take control of this disease."
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins